Search

Your search keyword '"Cavanna A"' showing total 636 results
Start Over Author "Cavanna A" Publisher elsevier bv
636 results on '"Cavanna A"'

1. Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study

Author

Iacovino, Maria Lucia, primary, Celant, Simone, additional, Tomassini, Luca, additional, Arenare, Laura, additional, Caglio, Andrea, additional, Canciello, Andrea, additional, Salerno, Flavio, additional, Olimpieri, Pier Paolo, additional, Di Segni, Susanna, additional, Sferrazza, Antonella, additional, Piccirillo, Maria Carmela, additional, Beretta, Giordano Domenico, additional, Pinto, Carmine, additional, Blasi, Livio, additional, Cinieri, Saverio, additional, Cavanna, Luigi, additional, Di Maio, Massimo, additional, Russo, Pierluigi, additional, and Perrone, Francesco, additional

Published
2024
Full Text
View/download PDF

3. Contralateral Prophylactic Mastectomy and Oophorectomy Increase the Survival in Brca-Related Breast Cancer: The Italian Mutina Study

Author

Cortesi, Laura, primary, Cortesi, Giulia, additional, Venturelli, Marta, additional, Toss, Angela, additional, Barbieri, Elena, additional, Tamburrano, Fabio, additional, Musolino, Antonino, additional, De Giorgi, Ugo, additional, Bisagni, Giancarlo, additional, Arcangeli, Valentina, additional, zamagni, claudio, additional, Cavanna, Luigi, additional, and Dominici, Massimo, additional

Published
2024
Full Text
View/download PDF

4. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Borghaei, H., primary, de Marinis, F., additional, Dumoulin, D., additional, Reynolds, C., additional, Theelen, W.S.M.E., additional, Percent, I., additional, Gutierrez Calderon, V., additional, Johnson, M.L., additional, Madroszyk-Flandin, A., additional, Garon, E.B., additional, He, K., additional, Planchard, D., additional, Reck, M., additional, Popat, S., additional, Herbst, R.S., additional, Leal, T.A., additional, Shazer, R.L., additional, Yan, X., additional, Harrigan, R., additional, Peters, S., additional, Abdel-Karim, Isam, additional, Abdelsalam, Mahmoud, additional, Addeo, Alfredo, additional, Aguado, Carlos, additional, Alexander, Patrick, additional, Alt, Jürgen, additional, Azzi, Georges, additional, Balaraman, Rama, additional, Biesma, Bonne, additional, Blackhall, Fiona, additional, Bohnet, Sabine, additional, Boleti, Ekaterini, additional, Borghaei, Hossein, additional, Bradbury, Penelope, additional, Brighenti, Matteo, additional, Campbell, Nicholas, additional, Campbell, Toby, additional, Canon, Jean-Luc, additional, Cappuzzo, Federico, additional, Costa, Enric Carcereny, additional, Cavanna, Luigi, additional, Cetnar, Jeremy, additional, Chella, Antonio, additional, Chouaid, Christos, additional, Christoph, Daniel, additional, Castán, Javier Cortés, additional, Dakhil, Shaker, additional, de Castro Carpeño, Francisco Javier, additional, de Marinis, Filippo, additional, Delmonte, Angelo, additional, Demedts, Ingel, additional, Demey, Wim, additional, Dits, Joyce, additional, del Pilar Diz Taín, Maria, additional, Gómez, Manuel Dómine, additional, Dorius, Timothy, additional, Dumoulin, Daphne, additional, Duruisseaux, Michaël, additional, Eaton, Keith, additional, González, Emilio Esteban, additional, Evans, Devon, additional, Faehling, Martin, additional, Farrell, Nicholas, additional, Feinstein, Trevor, additional, Font, Enriqueta Felip, additional, Garcia Campelo, Maria Rosario, additional, Garon, Edward, additional, Garrido López, María Pilar, additional, Germonpré, Paul, additional, Gersten, Todd, additional, Cao, Maria Gonzalez, additional, Gopaluni, Srivalli, additional, Greillier, Laurent, additional, Grossi, Francesco, additional, Guisier, Florian, additional, Gurubhagavatula, Sarada, additional, Calderón, Vanesa Gutiérrez, additional, Hakimian, David, additional, Hall, Richard, additional, Hao, Desirée, additional, Harris, Ronald, additional, Hashemi, Sayed, additional, He, Kai, additional, Hendriks, Lizza, additional, Huang, Chao, additional, Ibrahim, Emad, additional, Jain, Sharad, additional, Johnson, Melissa, additional, Jones, Benjamin, additional, Jones, Monte, additional, Juan Vidal, Óscar José, additional, Juergens, Rosalyn, additional, Kaderbhai, Courèche, additional, Kastelijn, Elisabeth A (Lisanne), additional, Keresztes, Roger, additional, Kio, Ebenezer, additional, Kokowski, Konrad, additional, Konduri, Kartik, additional, Kulkarni, Swati, additional, Kuon, Jonas, additional, Kurkjian, Carla, additional, Labbé, Catherine, additional, Lerner, Rachel, additional, Lim, Farah, additional, Madroszyk-Flandin, Anne, additional, Marathe, Omkar, additional, Martincic, Danko, additional, McClay, Edward, additional, McIntyre, Kristi, additional, Mekhail, Tarek, additional, Misino, Andrea, additional, Molinier, Olivier, additional, Morabito, Alessandro, additional, Morócz, Éva, additional, Müller, Veronika, additional, Nagy, Tünde, additional, Nguyen, Anthony V., additional, Nidhiry, Emmanuel, additional, Okazaki, Ian, additional, Ortega-Granados, Ana Laura, additional, Ostoros, Gyula, additional, Oubre, David, additional, Owen, Scott, additional, Pachipala, Krishna, additional, Park, David, additional, Patel, Pareshkumar, additional, Percent, Ivor, additional, Pérol, Maurice, additional, Peters, Solange, additional, Piet, Berber, additional, Planchard, David, additional, Polychronis, Andreas, additional, Aix, Santiago Ponce, additional, Pons-Tostivint, Elvire, additional, Popat, Sanjaykumar, additional, Pulla, Mariano Provencio, additional, Quantin, Xavier, additional, Quéré, Gilles, additional, Rafique, Noman, additional, Ramaekers, Ryan, additional, Reck, Martin, additional, Reiman, Anthony, additional, Reinmuth, Niels, additional, Reynolds, Craig, additional, Rodríguez-Abreu, Delvys, additional, Romano, Gianpiero, additional, Roque, Tammy, additional, Salzberg, Matthew, additional, Sanborn, Rachel, additional, Sandiego, Sergio, additional, Schaefer, Eric, additional, Schreeder, Marshall, additional, Seetharamu, Nagashree, additional, Seneviratne, Lasika, additional, Shah, Purvi, additional, Shunyakov, Leonid, additional, Slater, Dennis, additional, Parra, Hector Soto, additional, Stigt, Johannes, additional, Stilwill, Joseph, additional, Su, Jingdong, additional, Surmont, Veerle, additional, Swink, Alicia, additional, Szalai, Zsuzsanna, additional, Talbot, Toby, additional, Garcia, Alvaro Taus, additional, Theelen, Willemijn, additional, Thompson, Jonathan, additional, Tiseo, Marcello, additional, Uprety, Dipesh, additional, Uyeki, James, additional, van der Leest, Kornelius Cor, additional, Van Ho, Anthony, additional, van Putten, John, additional, Estévez, Sergio Vázquez, additional, Veatch, Andrea, additional, Vergnenègre, Alain, additional, Ward, Patrick, additional, Weise, Amy, additional, Weiss, Matthias, additional, Whitehurst, Matthew, additional, Zai, Silvia, additional, Zalcman, Gérard, additional, and Zuniga, Richard, additional

Published
2023
Full Text
View/download PDF

5. Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

Author

Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H. Coschi, Federica Grosso, Marie Florescu, Manlio Mencoboni, John R. Goffin, Maria Pagano, Fortunato Ciardiello, Fabiana Letizia Cecere, Mark Vincent, Roberto Ferrara, David E. Dawe, Desiree Hao, Christopher W. Lee, Alessandro Morabito, Cesare Gridelli, Luigi Cavanna, Mussawar Iqbal, Normand Blais, Natasha B. Leighl, Paul Wheatley-Price, Ming-Sound Tsao, Francesca Ugo, Hazem El-Osta, Piera Gargiulo, Pierre-Olivier Gaudreau, Dongsheng Tu, Joana Sederias, Pamela Brown-Walker, Francesco Perrone, Lesley Seymour, and Scott A. Laurie

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2023
Full Text
View/download PDF

6. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Author

Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, Alessandra Ferro, Claudia Proto, Raffaele Costanzo, Manolo D’Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo De Marinis, Lucio Crinò, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito, Piccirillo, Maria Carmela, Bonanno, Laura, Garassino, Marina Chiara, Esposito, Giovanna, Dazzi, Claudio, Cavanna, Luigi, Burgio, Marco Angelo, Rosetti, Francesco, Rizzato, Simona, Morgillo, Floriana, Cinieri, Saverio, Veccia, Antonello, Papi, Maximilan, Tonini, Giuseppe, Gebbia, Vittorio, Ricciardi, Serena, Pozzessere, Daniele, Ferro, Alessandra, Proto, Claudia, Costanzo, Raffaele, D'Arcangelo, Manolo, Proietto, Manuela, Gargiulo, Piera, Di Liello, Raimondo, Arenare, Laura, De Marinis, Filippo, Crinò, Lucio, Ciardiello, Fortunato, Normanno, Nicola, Gallo, Ciro, Perrone, Francesco, Gridelli, Cesare, and Morabito, Alessandro

Subjects
Pulmonary and Respiratory Medicine, Lung Neoplasms, EGFR, NSCLC, Bevacizumab, ErbB Receptors, Erlotinib Hydrochloride, Oncology, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Mutation, Humans, Randomized clinical trial, Protein Kinase Inhibitors
Abstract

Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomized, phase 3 investigating the addition of bevacizumab to erlotinib as first-line treatment of advanced EGFR-mutated NSCLC.Eligible patients were randomized 1:1 to erlotinib plus bevacizumab or erlotinib alone. Investigator-assessed PFS and blinded independent centrally reviewed PFS were coprimary end points. With 80% power in detecting a 0.60 hazard ratio and two-sided α error of 0.05, 126 events of 160 patients were needed. The trial was registered as NCT02633189 and EudraCT 2015-002235-17.From April 11, 2016, to February 27, 2019, a total of 160 patients were randomized to erlotinib plus bevacizumab (80) or erlotinib alone (80). At a median follow-up of 36.3 months, median investigator-assessed PFS was 15.4 months (95% confidence interval [CI]: 12.2-18.6) with erlotinib plus bevacizumab and 9.6 months (95% CI: 8.2-10.6) with erlotinib alone (hazard ratio = 0.66, 95% CI: 0.47-0.92). Blinded independent centrally reviewed PFS analysis confirmed this result. A statistically significant interaction with treatment effect was found for smoking habit (p = 0.0323), with PFS prolongation being clinically significant only among current or previous smokers. Hypertension (grade ≥3: 24% versus 5%), skin rash (grade ≥ 3: 31% versus 14%), thromboembolic events (any grade: 11% versus 4%), and proteinuria (any grade: 23% versus 6%) were more frequent with the combination.The addition of bevacizumab to first-line erlotinib prolonged PFS in Italian patients with EGFR-mutated NSCLC; toxicity was increased with the combination but without unexpected safety issues.

Published
2022
Full Text
View/download PDF

9. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, M., primary, Giommoni, E., additional, Bergamo, F., additional, Milella, M., additional, Cavanna, L., additional, Di Marco, M.C., additional, Spada, M., additional, Cordio, S., additional, Aprile, G., additional, Cardellino, G.G., additional, Maiello, E., additional, Bernardini, I., additional, Ghidini, M., additional, Bozzarelli, S., additional, Macchini, M., additional, Orsi, G., additional, De Simone, I., additional, Rulli, Er., additional, Porcu, L., additional, Torri, V., additional, Pinto, C., additional, Reni, Michele, additional, Macchini, Marina, additional, Orsi, Giulia, additional, Peretti, Umberto, additional, Valente, Mariamaddalena, additional, Giommoni, Elisa, additional, Antonuzzo, Lorenzo, additional, Di Costanzo, Francesco, additional, Bergamo, Francesca, additional, Zagonel, Vittorina, additional, Lonardi, Sara, additional, Buggin, Federica, additional, Milella, Michele, additional, Palmerio, Silvia, additional, Cavanna, Luigi, additional, Di Nunzio, Camilla, additional, Di Marco, Maria Cristina, additional, Grassi, Elisa, additional, Spada, Massimiliano, additional, Messina, Marco, additional, Cordio, Stefano, additional, Avola, Francesco, additional, Aprile, Giuseppe, additional, Pagano, Salvatore, additional, Simionato, Francesca, additional, Cardellino, Giovanni Gerardo, additional, Majer, Federica, additional, Maiello, Evaristo, additional, Latiano, Tiziana Pia, additional, Chiarazzo, Cinzia, additional, Artioli, Fabrizio, additional, Razzini, Giorgia, additional, Pasqualini, Antonella, additional, Ghidini, Michele, additional, Binda, Elisa, additional, Lazzarelli, Silvia, additional, Bozzarelli, Silvia, additional, Sala, Simona, additional, Luppi, Gabriele, additional, Pettorelli, Elisa, additional, Spallanzani, Andrea, additional, Vicario, Giovanni, additional, Salmaso, Flavia, additional, Basso, Marco, additional, Silvestris, Nicola, additional, Del Curatolo, Sabina, additional, Zustovich, Fable, additional, Bongiovanni, Francesca, additional, Longobardi, Ciro, additional, Sandi, Ilenia, additional, Fontanella, Caterina, additional, Montelatici, Silvia, additional, Giordano, Monica, additional, Luchena, Giovanna, additional, Gilardoni, Micol, additional, Tamburini, Emiliano, additional, Rudnas, Britt, additional, Venturini, Barbara, additional, Merelli, Barbara, additional, Negrini, Giorgia, additional, Vici, Elio Maria, additional, Marabese, Alessandra, additional, Garetto, Cristina, additional, Curcio, Paola, additional, Cinieri, Saverio, additional, Cinefra, Margherita, additional, Ferrara, Pasqualinda, additional, Cantore, Maurizio, additional, Morselli, Patrizia, additional, Fumi, Guglielmo, additional, Isidori, Agnese, additional, Ciccarese, Giovanni, additional, Paolo Frassineti, Giovanni Luca, additional, Pagan, Flavia, additional, Vaccaro, Vanja, additional, Spoto, Chiara, additional, Ferrara, Marianna, additional, Garufi, Carlo, additional, Caporale, Marta, additional, Vasile, Enrico, additional, Salani, Francesca, additional, Barone, Elisa, additional, Berardi, Rossana, additional, Onofri, Azzurra, additional, Ballatore, Zelmira, additional, Lucarelli, Alessandra, additional, Barucca, Alessandra, additional, Pancotti, Amedeo, additional, Scipioni, Teresa, additional, Bencardino, Katia, additional, Marrapese, Giovanna, additional, Idotta, Laura, additional, Petrelli, Fausto, additional, Lonati, Veronica, additional, Ceribelli, Anna, additional, Giuli, Angelo, additional, Zannori, Cristina, additional, Bassanelli, Maria, additional, Mambrini, Andrea, additional, Ginocchi, Laura, additional, Orlandi, Massimo, additional, Celio, Luigi, additional, Niger, Monica, additional, Biamonte, Lavinia, additional, Tamberi, Stefano, additional, Piancastelli, Alessandra, additional, Papiani, Giorgio, additional, Valli, Irene, additional, Allione, Paolo, additional, Boe, Maria Giovanna, additional, Scartozzi, Mario, additional, Lai, Eleonora, additional, Pireddu, Annagrazia, additional, Ziranu, Pina, additional, Demurtas, Laura, additional, Puzzoni, Marco, additional, Mariani, Stefano, additional, Pretta, Andrea, additional, Liscia, Nicole, additional, Savastano, Clementina, additional, Malaspina, Valentina, additional, Tonini, Giuseppe, additional, Grassani, Teresa, additional, Barco, Barbara, additional, Pierosandro, Tagliaferri, additional, Ciliberto, Domenico, additional, Ierardi, Antonella, additional, Calandruccio, Natale Daniele, additional, Minotti, Vincenzo, additional, Matocci, Roberta, additional, Torri, Valter, additional, Porcu, Luca, additional, Rulli, Erica, additional, De Simone, Irene, additional, Carlucci, Luciano, additional, Rulli, Eliana, additional, Poli, Davide, additional, Tonto, Paola, additional, Scellato, Francesca, additional, and Pinto, Carmine, additional

Published
2023
Full Text
View/download PDF

10. Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).

Author

Piccirillo, Maria Carmela, primary, Chu, Quincy, additional, Bradbury, Penelope, additional, Tu, Wei, additional, Coschi, Courtney H., additional, Grosso, Federica, additional, Florescu, Marie, additional, Mencoboni, Manlio, additional, Goffin, John R., additional, Pagano, Maria, additional, Ciardiello, Fortunato, additional, Cecere, Fabiana Letizia, additional, Vincent, Mark, additional, Ferrara, Roberto, additional, Dawe, David E., additional, Hao, Desiree, additional, Lee, Christopher W., additional, Morabito, Alessandro, additional, Gridelli, Cesare, additional, Cavanna, Luigi, additional, Iqbal, Mussawar, additional, Blais, Normand, additional, Leighl, Natasha B., additional, Wheatley-Price, Paul, additional, Tsao, Ming-Sound, additional, Ugo, Francesca, additional, El-Osta, Hazem, additional, Gargiulo, Piera, additional, Gaudreau, Pierre-Olivier, additional, Tu, Dongsheng, additional, Sederias, Joana, additional, Brown-Walker, Pamela, additional, Perrone, Francesco, additional, Seymour, Lesley, additional, and Laurie, Scott A., additional

Published
2023
Full Text
View/download PDF

12. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Author

Del Mastro, Lucia, primary, Poggio, Francesca, additional, Blondeaux, Eva, additional, De Placido, Sabino, additional, Giuliano, Mario, additional, Forestieri, Valeria, additional, De Laurentiis, Michelino, additional, Gravina, Adriano, additional, Bisagni, Giancarlo, additional, Rimanti, Anita, additional, Turletti, Anna, additional, Nisticò, Cecilia, additional, Vaccaro, Angela, additional, Cognetti, Francesco, additional, Fabi, Alessandra, additional, Gasparro, Simona, additional, Garrone, Ornella, additional, Alicicco, Maria Grazia, additional, Urracci, Ylenia, additional, Mansutti, Mauro, additional, Poletti, Paola, additional, Correale, Pierpaolo, additional, Bighin, Claudia, additional, Puglisi, Fabio, additional, Montemurro, Filippo, additional, Colantuoni, Giuseppe, additional, Lambertini, Matteo, additional, Boni, Luca, additional, Venturini, M, additional, Abate, A, additional, Pastorino, S, additional, Canavese, G, additional, Vecchio, C, additional, Guenzi, M, additional, Lambertini, M, additional, Levaggi, A, additional, Giraudi, S, additional, Accortanzo, V, additional, Floris, C.A., additional, Aitini, E, additional, Fornari, G, additional, Miraglia, S, additional, Buonfanti, G, additional, Cherchi, M.C., additional, Petrelli, F, additional, Vaccaro, A, additional, Magnolfi, E, additional, Contu, A, additional, Labianca, R, additional, Parisi, A, additional, Basurto, C, additional, Cappuzzo, F, additional, Merlano, M, additional, Russo, S, additional, Mansutti, M, additional, Poletto, E, additional, Nardi, M, additional, Grasso, D, additional, Fontana, A, additional, Isa, L, additional, Comandè, M, additional, Cavanna, L, additional, Iacobelli, S, additional, Milani, S, additional, Mustacchi, G, additional, Venturini, S, additional, Scinto, A.F., additional, Sarobba, M.G., additional, Pugliese, P, additional, Bernardo, A, additional, Pavese, I, additional, Coccaro, M, additional, Massidda, B, additional, Ionta, M.T., additional, Nuzzo, A, additional, Laudadio, L, additional, Chiantera, V, additional, Dottori, R, additional, Barduagni, M, additional, Castiglione, F, additional, Ciardiello, F, additional, Tinessa, V, additional, Ficorella, A, additional, Moscetti, L, additional, Vallini, I, additional, Giardina, G, additional, Silva, R, additional, Montedoro, M, additional, Seles, E, additional, Morano, F, additional, Cruciani, G, additional, Adamo, V, additional, Pancotti, A, additional, Palmisani, V, additional, Ruggeri, A, additional, Cammilluzzi, E, additional, Carrozza, F, additional, D'Aprile, M, additional, Brunetti, M, additional, Gallotti, P, additional, Chiesa, E, additional, Testore, F, additional, D'Arco, A, additional, Ferro, A, additional, Jirillo, A, additional, Pezzoli, M, additional, Scambia, G, additional, Iacono, C, additional, Masullo, P, additional, Tomasello, G, additional, Gandini, G, additional, Zoboli, A, additional, Bottero, C, additional, Cazzaniga, M, additional, Genua, G, additional, Palazzo, S, additional, D'Amico, M, additional, and Perrone, D, additional

Published
2022
Full Text
View/download PDF

13. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern

Author

Lasagna, A., primary, Bergami, F., additional, Lilleri, D., additional, Percivalle, E., additional, Quaccini, M., additional, Serra, F., additional, Comolli, G., additional, Sarasini, A., additional, Sammartino, J.C., additional, Ferrari, A., additional, Arena, F., additional, Secondino, S., additional, Cicognini, D., additional, Schiavo, R., additional, Lo Cascio, G., additional, Cavanna, L., additional, Baldanti, F., additional, Pedrazzoli, P., additional, and Cassaniti, I., additional

Published
2022
Full Text
View/download PDF

14. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Author

M.E. Cazzaniga, G. Pinotti, E. Montagna, D. Amoroso, R. Berardi, A. Butera, K. Cagossi, L. Cavanna, M. Ciccarese, S. Cinieri, E. Cretella, E. De Conciliis, A. Febbraro, F. Ferraù, A. Ferzi, G. Fiorentini, A. Fontana, A.R. Gambaro, O. Garrone, V. Gebbia, D. Generali, L. Gianni, F. Giovanardi, A. Grassadonia, V. Leonardi, P. Marchetti, E. Melegari, A. Musolino, M. Nicolini, C. Putzu, F. Riccardi, D. Santini, S. Saracchini, M.G. Sarobba, M.G. Schintu, G. Scognamiglio, P. Spadaro, C. Taverniti, D. Toniolo, P. Tralongo, A. Turletti, R. Valenza, M.R. Valerio, P. Vici, L. Clivio, V. Torri, F. Cicchiello, F. Riva, I. Vallini, M. Mazza, C. Bonfadini, E. Bordin, M. Canicattì, F. Cappuccio, E. Collovà, C. De Angelis, R. Desorte, S. Donati, G. Drudi, D. Galanti, C. Mocerino, L. Orlando, B. Pellegrino, L. Pizzuti, C. Ridolfi, A. Rocca, D. Sarti, I. Spagnoletti, N. Tinari, A. Vandone, L. Vizzini, Cazzaniga M.E., Pinotti G., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Fiorentini G., Fontana A., Gambaro A.R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Melegari E., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M.G., Schintu M.G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M.R., Vici P., Clivio L., Torri V., Cicchiello F., Riva F., Vallini I., Mazza M., Bonfadini C., Bordin E., Canicatti M., Cappuccio F., Collova E., De Angelis C., Desorte R., Donati S., Drudi G., Galanti D., Mocerino C., Orlando L., Pellegrino B., Pizzuti L., Ridolfi C., Rocca A., Sarti D., Spagnoletti I., Tinari N., Vandone A., Vizzini L., Cazzaniga, M, Pinotti, G, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Fiorentini, G, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Melegari, E, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cicchiello, F, Riva, F, Vallini, I, Mazza, M, Bonfadini, C, Bordin, E, Canicatti, M, Cappuccio, F, Collova, E, De Angelis, C, Desorte, R, Donati, S, Drudi, G, Galanti, D, Mocerino, C, Orlando, L, Pellegrino, B, Pizzuti, L, Ridolfi, C, Rocca, A, Sarti, D, Spagnoletti, I, Tinari, N, Vandone, A, and Vizzini, L

Subjects
Adult, Oncology, medicine.medical_specialty, Cyclophosphamide, Settore MED/06 - Oncologia Medica, Antineoplastic Agents, Breast Neoplasms, Vinorelbine, Drug Administration Schedule, Antineoplastic Agent, Efficacy, Capecitabine, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Retrospective Studie, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Progression-free survival, Retrospective Studies, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocol, business.industry, Metronomic chemotherapy, General Medicine, Middle Aged, medicine.disease, Metastatic breast cancer, Metronomic Chemotherapy, Survival Rate, Methotrexate, Treatment Outcome, 030220 oncology & carcinogenesis, MED/06 - ONCOLOGIA MEDICA, Female, Surgery, business, Breast Neoplasm, Human, medicine.drug
Abstract

Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.

Published
2019
Full Text
View/download PDF

15. Sensory symptoms in body-focused repetitive behaviors, restless legs syndrome, and Tourette syndrome: An overlap?

Author

James Badenoch, Tamara Searle, Andrea E. Cavanna, Iona Watson, Badenoch, J, Searle, T, Watson, I, and Cavanna, A

Subjects
Tics, Cognitive Neuroscience, Body-focused repetitive behavior, Tourette syndrome, Trichotillomania, 03 medical and health sciences, Behavioral Neuroscience, 0302 clinical medicine, mental disorders, Basal ganglia, Humans, Medicine, 0501 psychology and cognitive sciences, Sensory symptom, 050102 behavioral science & comparative psychology, Restless legs syndrome, Cerebral Cortex, Tic, Dysesthesia, business.industry, Putamen, 05 social sciences, medicine.disease, Neuropsychology and Physiological Psychology, Tic Disorders, Posterior cingulate, Premonitory urge, medicine.symptom, business, Neuroscience, Insula, 030217 neurology & neurosurgery
Abstract

Tourette syndrome (TS) is a neurodevelopmental condition characterized by multiple tics. Sensory symptoms play a key role in the clinical phenomenology and pathophysiology of TS, as most patients report premonitory urges driving tic expression. Interestingly, sensory symptoms have also been reported in other conditions characterized by repeated behaviors. This review explores the nature of sensory symptoms reported by patients with body focused repetitive behaviors (BFRBs, especially trichotillomania and skin picking disorder) and restless legs syndrome (RLS) in comparison to TS. A sense of mounting inner tension and reinforcement mechanisms driven by gratification and relief on expression of the tic or repetitive behavior appear to be implicated across all conditions. Subjective urges can be temporarily suppressed by patients with TS and selected BFRBs, whereas patients with RLS tend to report dysesthesia more frequently than a suppressible urge to move. The observed similarities in the phenomenology of sensory symptoms across these conditions raise the possibility of a comparable underlying pathophysiology. Preliminary findings suggest an overlap of neural pathways encompassing the insula, basal ganglia (putamen), and posterior cingulate cortex.

Published
2020
Full Text
View/download PDF

16. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Author

Piccirillo, Maria Carmela, primary, Bonanno, Laura, additional, Garassino, Marina Chiara, additional, Esposito, Giovanna, additional, Dazzi, Claudio, additional, Cavanna, Luigi, additional, Burgio, Marco Angelo, additional, Rosetti, Francesco, additional, Rizzato, Simona, additional, Morgillo, Floriana, additional, Cinieri, Saverio, additional, Veccia, Antonello, additional, Papi, Maximilan, additional, Tonini, Giuseppe, additional, Gebbia, Vittorio, additional, Ricciardi, Serena, additional, Pozzessere, Daniele, additional, Ferro, Alessandra, additional, Proto, Claudia, additional, Costanzo, Raffaele, additional, D’Arcangelo, Manolo, additional, Proietto, Manuela, additional, Gargiulo, Piera, additional, Di Liello, Raimondo, additional, Arenare, Laura, additional, De Marinis, Filippo, additional, Crinò, Lucio, additional, Ciardiello, Fortunato, additional, Normanno, Nicola, additional, Gallo, Ciro, additional, Perrone, Francesco, additional, Gridelli, Cesare, additional, and Morabito, Alessandro, additional

Published
2022
Full Text
View/download PDF

18. Prevalence and clinical correlates of non-convulsive status epilepticus in elderly patients with acute confusional state: A systematic literature review

Author

Manfredonia, F, Saturno, E, Lawley, A, Gasverde, S, Cavanna, A, Manfredonia F, Saturno E, Lawley A, Gasverde S, Cavanna A, Manfredonia, F, Saturno, E, Lawley, A, Gasverde, S, Cavanna, A, Manfredonia F, Saturno E, Lawley A, Gasverde S, and Cavanna A

Abstract

Non-convulsive status epilepticus (NCSE) is a potentially treatable condition that poses considerable diagnostic challenges. NCSE is thought to be more common in the elderly than in the general population, however additional diagnostic challenges complicate its recognition in older patients, because of the wide differential diagnosis with common underlying causes of acute confusional state in this age group. We set out to review the existing evidence on the clinical correlates of NCSE in the elderly population. A systematic literature review was conducted according to the methodological standards outlined in the PRISMA statement to assess the clinical correlates of NCSE in patients aged 60 or older. Our literature search identified 11 relevant studies, which confirmed that the incidence of NCSE increases with age, in particular with regard to focal forms with impairment of consciousness. Female gender, history of epilepsy (or a recently witnessed seizure with motor features), and abnormal ocular movements appeared to correlate with the diagnosis of NCSE in the elderly, prompting prioritization of electroencephalography tests for diagnostic confirmation. Epidemiological data in the elderly vary widely because of the heterogeneity of definitions and diagnostic criteria applied across different studies. Based on our findings, it is recommended to keep a low threshold for requesting electroencephalography tests to confirm the diagnosis of NCSE in elderly patients with acute confusional state, even in the presence of a presumed symptomatic cause.

Published
2020

19. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count

Author

Stefania Paolucci, Irene Cassaniti, Federica Novazzi, Loretta Fiorina, Antonio Piralla, Giuditta Comolli, Raffaele Bruno, Renato Maserati, Roberto Gulminetti, Stefano Novati, Francesco Mojoli, Fausto Baldanti, R Bruno, M Mondelli, E Brunetti, A Di Matteo, E Seminari, L Maiocchi, V Zuccaro, L Pagnucco, B Mariani, S Ludovisi, R Lissandrin, A Parisi, P Sacchi, SFA Patruno, G Michelone, R Gulminetti, D Zanaboni, S Novati, R Maserati, P Orsolini, M Vecchia, M Sciarra, E Asperges, M Colaneri, A Di Filippo, M Sambo, S Biscarini, M Lupi, S Roda, TC Pieri, I Gallazzi, M Sachs, P Valsecchi, S Perlini, C Alfano, M Bonzano, F Briganti, G Crescenzi, AG Falchi, R Guarnone, B Guglielmana, E Maggi, I Martino, P Pettenazza, S Pioli di Marco, F Quaglia, A Sabena, F Salinaro, F Speciale, I Zunino, M De Lorenzo, G Secco, L Dimitry, G Cappa, I Maisak, B Chiodi, M Sciarrini, B Barcella, F Resta, L Moroni, G Vezzoni, L Scattaglia, E Boscolo, C Zattera, MF Tassi, V Capozza, D Vignaroli, M Bazzini, G Iotti, F Mojoli, M Belliato, L Perotti, S Mongodi, G Tavazzi, G Marseglia, A Licari, I Brambilla, D Barbarini, A Bruno, P Cambieri, G Campanini, C. Cavanna, G Comolli, M Corbella, R Daturi, M Furione, P Marone, E Monzillo, S Paolucci, M Parea, E Percivalle, A Piralla, F Rovida, A Sarasini, M Zavattoni, G Adzasehoun, M Ardizzone, L Bellotti, V Brunco, E Cabano, G Casali, L Capella, D Devitis, L Dossena, G Frisco, G Garbagnoli, F Gardellini, A Girello, A Guerrizio, V Landini, C Lucchelli, V Maliardi, P Piemontese, S Pezzaia, M Premoli, C Rebuffa, C Zanello, J Bagnarino, F Bergami, A Bonetti, G Caneva, I Cassaniti, A Corcione, R Di Martino, A Di Napoli, A Ferrari, G Ferrari, L Fiorina, A Gallone, F Giardina, A Girardi, A Mercato, C Merla, F Novazzi, G Ratano, B Rossi, G Saveriaempillai, IM Sciabica, M Tallarita, E Vecchio Nepita, J Vitali, A Cerino, S Varchetta, B Oliviero, S Mantovani, D Mele, M Calvi, M Tizzoni, C Nicora, A Triarico, V Petronella, C Marena, A Muzzi, P Lago, S Cutti, V Novelli, F Comandatore, G BatistiBiffignandi, S Gaiarsa, M Rettani, and C Bandi

Subjects
Male, 0301 basic medicine, Human cytomegalovirus, Herpesvirus 4, Human, Epstein-Barr Virus Infections, viruses, Lymphocyte, COVID-19, EBV DNA, Lymphocyte subpopulation, Aged, Aged, 80 and over, CD8-Positive T-Lymphocytes, DNA, Viral, Female, Humans, Intensive Care Units, Killer Cells, Natural, Lymphocyte Count, Lymphocyte Subsets, Middle Aged, Opportunistic Infections, Real-Time Polymerase Chain Reaction, SARS-CoV-2, Viral Load, law.invention, 0302 clinical medicine, law, 80 and over, Killer Cells, Cytotoxic T cell, Viral, 030212 general & internal medicine, biology, musculoskeletal, neural, and ocular physiology, General Medicine, Intensive care unit, Infectious Diseases, medicine.anatomical_structure, Natural, Human herpesvirus 6, Human, Microbiology (medical), 030106 microbiology, macromolecular substances, Article, Virus, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, medicine, lcsh:RC109-216, Parvovirus, business.industry, Herpesvirus 4, DNA, biology.organism_classification, medicine.disease, nervous system, Immunology, business, CD8
Abstract

Highlights • EBV reactivation was observed in patients with COVID-19. • NK + and CD8 + T cell reduction was related to the severity of COVID-19 infection. • An increase of B cells in patients with severe symptoms was documented., Objectives The immunologic profile and opportunistic viral DNA increase were monitored in Italian patients with COVID-19 in order to identify markers of disease severity. Methods A total of 104 patients infected with SARS-CoV-2 were evaluated in the study. Of them, 42/104 (40.4%) were hospitalized in an intensive care unit (ICU) and 62/104(59.6%) in a sub-intensive care unit (SICU). Human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV), Parvovirus B19 and Human Herpesvirus 6 virus reactivations were determined by real-time PCR, and lymphocyte subpopulation counts were determined by flow cytometry. Results Among opportunistic viruses, only EBV was consistently detected. EBV DNA was observed in 40/42 (95.2%) of the ICU patients and in 51/61 (83.6%) of the SICU patients. Comparing the two groups of patients, the EBV DNA median level among ICU patients was significantly higher than that observed in SICU patients. In parallel, a significant reduction of CD8 T cell and NK count in ICU patients as compared with SICU patients was observed (p

Published
2021
Full Text
View/download PDF

20. The role of electroencephalography in the early diagnosis of non-convulsive status epilepticus in elderly patients with acute confusional state: Two possible strategies?

Author

Andrew Lawley, Eleonora Saturno, Sabrina Gasverde, Andrea E. Cavanna, Francesco Manfredonia, Manfredonia, F, Saturno, E, Lawley, A, Gasverde, S, and Cavanna, A

Subjects
Male, medicine.medical_specialty, Clinical settings, Status epilepticus, Non-convulsive status epilepticu, Electroencephalography, 03 medical and health sciences, Epilepsy, Elderly, Status Epilepticus, 0302 clinical medicine, Elderly population, medicine, Humans, Clinical significance, Confusion, Intensive care medicine, Aged, Aged, 80 and over, medicine.diagnostic_test, business.industry, Convulsive status epilepticus, General Medicine, Middle Aged, Acute confusional state, medicine.disease, Early Diagnosis, Neurology, Female, Neurology (clinical), Differential diagnosis, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

Non-convulsive status epilepticus (NCSE) can pose considerable diagnostic challenges, especially in the elderly, because of the wide differential diagnosis with common underlying causes of acute confusional state in this age group. We reviewed the proposed electroencephalography (EEG) strategies to improve the diagnostic yield of non-convulsive status epilepticus in the elderly population. Specifically, a debated topic of clinical relevance is the exact role of the EEG in the early diagnosis of NCSE in the elderly. Two EEG strategies have been proposed to improve the diagnostic yield of NCSE: emergent abbreviated EEG (EAEEG) recordings with reduced montages, and continuous EEG (CEEG) monitoring. Both approaches appear to be potentially advantageous, but at the same time subject to intrinsic limitations. Our literature review found initial evidence that the diagnostic yield for NCSE of prolonged EEG recordings is superior to routine EEGs. Further research is needed to confirm these preliminary findings and to explore strategies to improve the feasibility of a more widespread use of prolonged recordings within acute clinical settings.

Published
2019
Full Text
View/download PDF

22. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

Author

Lasagna, A., primary, Bergami, F., additional, Lilleri, D., additional, Percivalle, E., additional, Quaccini, M., additional, Alessio, N., additional, Comolli, G., additional, Sarasini, A., additional, Sammartino, J.C., additional, Ferrari, A., additional, Arena, F., additional, Secondino, S., additional, Cicognini, D., additional, Schiavo, R., additional, Lo Cascio, G., additional, Cavanna, L., additional, Baldanti, F., additional, Pedrazzoli, P., additional, and Cassaniti, I., additional

Published
2022
Full Text
View/download PDF

23. Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey

Author

Alice Indini, Francesco Grossi, Luigi Cavanna, Alberto Scanni, Cinzia Ortega, Livio Blasi, Claudio Zamagni, Graziella Pinotti, Carlo Aschele, Luisa Fioretto, Vincenzo Montesarchio, Bruno Daniele, Monica Giordano, Mario Clerico, and Giammaria Fiorentini

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Telemedicine, Coronavirus disease 2019 (COVID-19), Cancer, Coronavirus, Health care, Infection, Pandemic, Disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Global health, business.industry, Public health, Triage, 030104 developmental biology, 030220 oncology & carcinogenesis, business
Abstract

The novel severe acute respiratory syndrome coronavirus-2 pandemic is a global health problem, which started to affect China by the end of 2019. In Europe, Italy has faced this novel disease entity (named novel coronavirus disease [COVID-19]) first and severely. COVID-19 represents a significant hurdle for public health services and a potential harm for patients with cancer. The Collegio Italiano dei Primari Oncologi Medici (CIPOMO) is an Italian association of head physicians in oncology departments, which promotes working and research activities in oncology on a national basis. In the midst of the epidemic in Italy, the CIPOMO promoted a national survey aiming to evaluate the impact of COVID-19 on clinical activity of oncologists and the implementation of containment measures of COVID-19 diffusion. Overall, 122 head physicians participated in this survey, with a homogeneous distribution on the national territory. Results show that the following measures for oncologic patients have been promptly implemented through the whole country: use of protective devices, triage of patients accessing the hospital, delay of non-urgent visits and use of telemedicine. Results of this survey suggest that Italian oncology departments have promptly set a proactive approach to the actual emergency. Oncologists need to preserve the continuum of care of patients, as the benefit of ensuring a well-delivered anti-cancer treatment plan outweighs the risk of COVID-19 infection. International cooperation is an important starting point, as heavily affected nations can serve as an example to find out ways to safely preserve health activity during the pandemic.

Published
2020
Full Text
View/download PDF

24. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up

Author

Lasagna, A., primary, Lilleri, D., additional, Agustoni, F., additional, Percivalle, E., additional, Borgetto, S., additional, Alessio, N., additional, Comolli, G., additional, Sarasini, A., additional, Bergami, F., additional, Sammartino, J.C., additional, Ferrari, A., additional, Zavaglio, F., additional, Arena, F., additional, Secondino, S., additional, Falzoni, M., additional, Schiavo, R., additional, Lo Cascio, G., additional, Cavanna, L., additional, Baldanti, F., additional, Pedrazzoli, P., additional, and Cassaniti, I., additional

Published
2022
Full Text
View/download PDF

25. Prevalence and clinical correlates of non-convulsive status epilepticus in elderly patients with acute confusional state: A systematic literature review

Author

Sabrina Gasverde, Eleonora Saturno, Andrea E. Cavanna, Francesco Manfredonia, Andrew Lawley, Manfredonia, F, Saturno, E, Lawley, A, Gasverde, S, and Cavanna, A

Subjects
Pediatrics, medicine.medical_specialty, Consciousness, Population, Status epilepticus, Electroencephalography, Non-convulsive status epilepticu, 03 medical and health sciences, Epilepsy, 0302 clinical medicine, Status Epilepticus, Elderly, Epidemiology, medicine, Prevalence, Humans, 030212 general & internal medicine, education, Confusion, Aged, education.field_of_study, medicine.diagnostic_test, business.industry, Incidence (epidemiology), Middle Aged, medicine.disease, Acute confusional state, Systematic review, Neurology, Female, Neurology (clinical), Differential diagnosis, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

Non-convulsive status epilepticus (NCSE) is a potentially treatable condition that poses considerable diagnostic challenges. NCSE is thought to be more common in the elderly than in the general population, however additional diagnostic challenges complicate its recognition in older patients, because of the wide differential diagnosis with common underlying causes of acute confusional state in this age group. We set out to review the existing evidence on the clinical correlates of NCSE in the elderly population. A systematic literature review was conducted according to the methodological standards outlined in the PRISMA statement to assess the clinical correlates of NCSE in patients aged 60 or older. Our literature search identified 11 relevant studies, which confirmed that the incidence of NCSE increases with age, in particular with regard to focal forms with impairment of consciousness. Female gender, history of epilepsy (or a recently witnessed seizure with motor features), and abnormal ocular movements appeared to correlate with the diagnosis of NCSE in the elderly, prompting prioritization of electroencephalography tests for diagnostic confirmation. Epidemiological data in the elderly vary widely because of the heterogeneity of definitions and diagnostic criteria applied across different studies. Based on our findings, it is recommended to keep a low threshold for requesting electroencephalography tests to confirm the diagnosis of NCSE in elderly patients with acute confusional state, even in the presence of a presumed symptomatic cause.

Published
2020

26. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Author

Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini, R., Balduzzi, S., D'Amico, R., Guarneri, Falci C, V., Giarratano, T, Mcmahon, L, De Salvo GL, Dieci, Mv, Maiorana, A, Ficarra, G, Caggia, F, Grisolia, D, Bartolini, S, Lorusso, V, Ardito, R, Tartarone, A, Vanella, P, Taverniti, C, Porpiglia, M, Spanu, Pg, Biglia, N, Andreis, D, Piancastelli, A, Fedeli, A, Parra, Hs, Gambaro, Ar, Romito, S, Malossi, A, Gori, S, Miglietta, L, Del Mastro, L, Amoroso, D, Mansutti, M, Generali, D, Prati, G, Bertolini, A, Berardi, R, Zanni, A, Cottafavi, L, Bologna, A, Naso, G, Pancotti, A, Farci, D, Zoboli, A, Silva, R, Laudadio, L, Bordonaro, R, Marenco, D, Dongiovanni, V, Baldini, E, Saggia, C, Gorzegno, G, Cariello, A, Biganzoli, L, Rampello, E., Conte P., Frassoldati A., Bisagni G., Brandes A.A., Donadio M., Garrone O., Piacentini F., Cavanna L., Giotta F., Aieta M., Gebbia V., Molino A., Musolino A., Ferro A., Maltoni R., Danese S., Zamagni C., Rimanti A., Cagossi K., Russo A., Pronzato P., Giovanardi F., Moretti G., Lombardo L., Schirone A., Beano A., Amaducci L., Bajardi E.A., Vicini R., Balduzzi S., D'Amico R., and Guarneri V.

Subjects
Oncology, Time Factors, Adjuvant, Breast cancer, Cardiac safety, De-escalated treatment, Trastuzumab, Settore MED/06 - Oncologia Medica, Receptor, ErbB-2, medicine.medical_treatment, Anthracycline, 030204 cardiovascular system & hematology, Breast cancer, Antineoplastic Agents, Immunological, ErbB-2, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Anthracyclines, skin and connective tissue diseases, Adjuvant, Mastectomy, Cardiac safety, De-escalated treatment, Hazard ratio, Hematology, Middle Aged, Chemotherapy regimen, Bridged-Ring Compound, Immunological, Local, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Taxoids, Trastuzumab, adjuvant, breast cancer, cardiac safety, de-escalated treatment, Breast Neoplasm, Human, Receptor, medicine.drug, Adult, Bridged-Ring Compounds, medicine.medical_specialty, Time Factor, Socio-culturale, Breast Neoplasms, Antineoplastic Agents, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Taxoid, Internal medicine, medicine, Humans, Chemotherapy, Risk factor, Aged, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocol, business.industry, medicine.disease, Cardiotoxicity, Neoplasm Recurrence, Neoplasm Recurrence, Local, business
Abstract

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)

Published
2018
Full Text
View/download PDF

27. Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder

Author

Raphaëlle Richieri, Christophe Lançon, Jean Régis, Graham Blackman, Giorgio Spatola, Andrea E. Cavanna, Richard Musil, Richieri, R, Blackman, G, Musil, R, Spatola, G, Cavanna, A, Lançon, C, and Régis, J

Subjects
Obsessive-Compulsive Disorder, medicine.medical_specialty, Deep brain stimulation, Internal capsule, Deep Brain Stimulation, medicine.medical_treatment, Capsulotomy, Gamma knife, Radiosurgery, Tourette syndrome, 03 medical and health sciences, 0302 clinical medicine, Refractory, Internal Capsule, Obsessive compulsive, mental disorders, medicine, Humans, 030212 general & internal medicine, business.industry, General Medicine, Middle Aged, medicine.disease, Surgery, Obsessive compulsive disorder, Treatment Outcome, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, Tourette Syndrome
Abstract

We report the first case of a patient with severe, intractable Tourette Syndrome with comorbid Obsessive Compulsive disorder, who recovered from both disorders with gamma-knife (GK) stereotactic radiosurgery following deep brain stimulation (DBS). This case highlights the possible role of the internal capsule within the neural circuitries underlying both TS and OCD, and suggests that in cases of treatment-refractory TS and comorbid OCD, bilateral anterior capsulotomy using stereotactic radiosurgery may be a viable treatment option.

Published
2018
Full Text
View/download PDF

28. Sensory aspects of Tourette syndrome

Author

Stefano Seri, Andrea E. Cavanna, Joanna H Cox, Cox, J, Seri, S, and Cavanna, A

Subjects
Tics, Cognitive Neuroscience, media_common.quotation_subject, Insula, Sensorimotor area, Sensory system, Severity of Illness Index, Tourette syndrome, 03 medical and health sciences, Behavioral Neuroscience, 0302 clinical medicine, Perception, Severity of illness, medicine, Humans, Motor Manifestations, media_common, Cerebral Cortex, Tic, business.industry, medicine.disease, Sensorimotor Areas, 030227 psychiatry, Multimodal hypersensitivity, Neuropsychology and Physiological Psychology, Sensory Thresholds, Tic Disorders, Premonitory urge, business, Neuroscience, 030217 neurology & neurosurgery, Tourette Syndrome
Abstract

Motor and vocal tics have long been recognised as the core features of Tourette syndrome (TS). However, patients’ first-person accounts have consistently reported that these involuntary motor manifestations have specific sensory correlates. These sensory symptoms are often described as feelings of mounting inner tension (“premonitory urges”) and are transiently relieved by tic expression. Multimodal hypersensitivity to external stimuli, perceived as triggers and/or exacerbating factors for specific tic symptoms, is also commonly reported by patients with TS. This article focuses on the rapidly expanding literature on the clinical and neurobiological aspects of the premonitory urge and multimodal hypersensitivity in patients with TS, with particular attention to pathophysiological mechanisms and possible treatment implications. These findings suggest that TS is a neurobehavioural condition characterised by intrinsic perceptual abnormalities involving the insula and sensorimotor areas, in addition to basal ganglia dysfunction. Further research will clarify the role of sensory symptoms in TS, as well as the effects of external sensory input on underlying motor abnormalities.

Published
2018
Full Text
View/download PDF

29. Evaluation of dexamethasone (DEX)-sparing regimens, administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in older patients receiving high-dose cisplatin

Author

Celio, L., primary, Cortinovis, D., additional, Cogoni, A.A., additional, Cavanna, L., additional, Martelli, O., additional, Carnio, S., additional, Collovà, E., additional, Bertolini, F., additional, Petrelli, F., additional, Cassano, A., additional, Chiari, R., additional, Zanelli, F., additional, Pisconti, S., additional, Vittimberga, I., additional, Letizia, A., additional, Misino, A., additional, Gernone, A., additional, Bonizzoni, E., additional, Pilotto, S., additional, De Placido, S., additional, and Bria, E., additional

Published
2021
Full Text
View/download PDF

30. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy

Author

Cavanna, Luigi, primary, Citterio, Chiara, additional, Biasini, Claudia, additional, Madaro, Serena, additional, Bacchetta, Nicoletta, additional, Lis, Anna, additional, Cremona, Gabriele, additional, Muroni, Monica, additional, Bernuzzi, Patrizia, additional, Lo Cascio, Giuliana, additional, Schiavo, Roberta, additional, Mutti, Martina, additional, Tassi, Maristella, additional, Mariano, Maria, additional, Trubini, Serena, additional, Bandieramonte, Giulia, additional, Maestri, Raffaella, additional, Mordenti, Patrizia, additional, Marazzi, Elisabetta, additional, and Vallisa, Daniele, additional

Published
2021
Full Text
View/download PDF

31. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Miles, D., primary, Ciruelos, E., additional, Schneeweiss, A., additional, Puglisi, F., additional, Peretz-Yablonski, T., additional, Campone, M., additional, Bondarenko, I., additional, Nowecki, Z., additional, Errihani, H., additional, Paluch-Shimon, S., additional, Wardley, A., additional, Merot, J.-L., additional, Trask, P., additional, du Toit, Y., additional, Pena-Murillo, C., additional, Revelant, V., additional, Klingbiel, D., additional, Bachelot, T., additional, Bouzid, K., additional, Desmoulins, I., additional, Coudert, B., additional, Glogowska, I., additional, Ciruelos Gil, E., additional, Dalenc, F., additional, Ricci, F., additional, Dieras, V., additional, Kaufman, B., additional, Ferreira, A., additional, Mano, M., additional, Kalofonos, H., additional, Andreetta, C., additional, Montemurro, F., additional, Barrett, S., additional, Zhang, Q., additional, Mavroudis, D., additional, Matus, J., additional, Villarreal Garza, C., additional, Beato, C., additional, Ismael, G., additional, Hu, X., additional, Abdel Azeem, H., additional, Gaafar, R., additional, Perrin, C., additional, Kerbrat, P., additional, Ettl, J., additional, Paepke, S., additional, Hitre, E., additional, Lang, I., additional, Trudeau, M., additional, Verma, S., additional, Li, H., additional, Hoffmann, O., additional, Aktas, B., additional, Cariello, A., additional, Cruciani, G., additional, Tienghi, A., additional, Tondini, C., additional, Al-Twegieri, T., additional, Loman, N., additional, Laing, R., additional, Miles, D., additional, Brain, E., additional, Fasching, P., additional, Lux, M., additional, Frassoldati, A., additional, Aziz, Z., additional, Salas, J., additional, Streb, J., additional, Krzemieniecki, K., additional, Wronski, A., additional, Garcia Garcia, J., additional, Menjon Beltran, S., additional, Cicin, I., additional, Schmid, P., additional, Gallagher, C., additional, Turner, N., additional, Tong, Z., additional, Boer, K., additional, Juhász, B., additional, Horvath, Z., additional, Bianchini, G., additional, Gianni, L., additional, Curigliano, G., additional, Juarez Ramiro, A., additional, Susnjar, S., additional, Matos, E., additional, Sevillano, E., additional, Garcia Estevez, L., additional, Gokmen, E., additional, Uslu, R., additional, Wildiers, H., additional, Schutz, F., additional, Cruz, M., additional, Bourgeois, H., additional, von Schumann, R., additional, Stemmer, S., additional, Dominguez, A., additional, Morales-Vásques, F., additional, Wojtukiewicz, M., additional, Trifunovic, J., additional, Echarri Gonzalez, M.J., additional, Illarramendi Mañas, J., additional, Martinez De Dueñas, E., additional, Voitko, N., additional, Hicks, J., additional, Waters, S., additional, Barrett-Lee, P., additional, Wheatley, D., additional, De Boer, R., additional, Cocquyt, V., additional, Jerusalem, G., additional, Barrios, C., additional, Panasci, L., additional, Mattson, J., additional, Tanner, M., additional, Gozy, M., additional, Vasilopoulos, G., additional, Papandreou, C., additional, Revesz, J., additional, Battelli, N., additional, Benedetti, G., additional, Latini, L., additional, Gridelli, C., additional, Lazaro Leon, J., additional, Alarcón Company, J., additional, Arance Fernandez, A., additional, Barnadas Molins, A., additional, Calvo Plaza, I., additional, Bratos, R., additional, Gonzalez Martin, A., additional, Izarzugaza Peron, Y., additional, Klint, L., additional, Kovalev, A., additional, McCarthy, N., additional, Yeo, B., additional, Kee, D., additional, Thomson, J., additional, White, S., additional, Greil, R., additional, Wang, S., additional, Artignan, X., additional, Juhasz-Böess, I., additional, Rody, A., additional, Ngan, R., additional, Dourleshter, F., additional, Goldberg, H., additional, Doni, L., additional, Di Costanzo, F., additional, Ferraù, F., additional, Drobniene, M., additional, Aleknavicius, E., additional, Rashid, K., additional, Costa, L., additional, de la Cruz Merino, L., additional, Garcia Saenz, J., additional, López, R., additional, Del Val Munoz, O., additional, Ozyilkan, O., additional, Azribi, F., additional, Jaafar, H., additional, Baird, R., additional, Verrill, M., additional, Beith, J., additional, Petzer, A., additional, Moreira de Andrade, J., additional, Bernstein, V., additional, Macpherson, N., additional, Rayson, D., additional, Saad Eldin, I., additional, Achille, M., additional, Augereau, P., additional, Müller, V., additional, Rasco, A., additional, Evron, E., additional, Katz, D., additional, Berardi, R., additional, Cascinu, S., additional, De Censi, A., additional, Gennari, A., additional, El-Saghir, N., additional, Ghosn, M., additional, Oosterkamp, H.M., additional, Van den Bosch, J., additional, Kukulska, M., additional, Kalinka, E., additional, Alonso, J., additional, Dalmau Portulas, E., additional, Del Mar Gordon Santiago, M., additional, Pelaez Fernandez, I., additional, Aksoy, S., additional, Altundag, K., additional, Senol Coskun, H., additional, Bozcuk, H., additional, Shparyk, Y., additional, Barraclough, L., additional, Levitt, N., additional, Panwar, U., additional, Kelly, S., additional, Rigg, A., additional, Varughese, M., additional, Castillo, C., additional, Fein, L., additional, Malik, L., additional, Stuart-Harris, R., additional, Singer, C., additional, Stoeger, H., additional, Samonigg, H., additional, Feng, J., additional, Cedeño, M., additional, Ruohola, J., additional, Berdah, J.-F., additional, Goncalves, A., additional, Orfeuvre, H., additional, Grischke, E.-M., additional, Simon, E., additional, Wagner, S., additional, Koumakis, G., additional, Papazisis, K., additional, Ben Baruch, N., additional, Fried, G., additional, Geffen, D., additional, Karminsky, N., additional, Peretz, T., additional, Cavanna, L., additional, Pedrazzioli, P., additional, Grasso, D., additional, Ruggeri, E., additional, D’Auria, G., additional, Moscetti, L., additional, Juozaityte, E., additional, Rodriguez Cid, J., additional, Roerdink, H., additional, Siddiqi, N., additional, Passos Coelho, J., additional, Arcediano Del Amo, A., additional, Garcia Garre, E., additional, García Gonzalez, M., additional, Garcia-Palomo Perez, A., additional, Herenandez Perez, C., additional, Lopez Alvarez, P., additional, Lopez De Ceballos, M.H., additional, Martínez Jañez, N., additional, Mele Olive, M., additional, McAdam, K., additional, Perren, T., additional, Dunn, G., additional, Humphreys, A., additional, Taylor, W., additional, Vera, R., additional, Kaen, L., additional, Andel, J., additional, Steger, G., additional, De Grève, J., additional, Huizing, M., additional, Hegg, R., additional, Joy, A., additional, Kuruvilla, P., additional, Sehdev, S., additional, Smiljanic, S., additional, Kütner, R., additional, Alexandre, J., additional, Grosjean, J., additional, Laplaige, P., additional, Largillier, R., additional, Maes, P., additional, Martin, P., additional, Pottier, V., additional, Christensen, B., additional, Khandan, F., additional, Lück, H.-J., additional, Zahm, D.-M., additional, Fountzilas, G., additional, Karavasilis, V., additional, Safra, T., additional, Inbar, M., additional, Ryvo, L., additional, Bonetti, A., additional, Seles, E., additional, Giacobino, A., additional, Chavarri Guerra, Y., additional, de Jongh, F., additional, van der Velden, A., additional, van Warmerdam, L., additional, Vrijaldenhoven, S., additional, Smorenburg, C.H., additional, Cavero, M., additional, Andres Conejero, R., additional, Oltra Ferrando, A., additional, Redondo Sanchez, A., additional, Ribelles Entrena, N., additional, Saura Grau, S., additional, Viñas Vilaro, G., additional, Bachmeier, K., additional, Beresford, M., additional, Butt, M., additional, Joffe, J., additional, Poole, C., additional, Woodings, P., additional, Chakraborti, P., additional, Yordi, G., additional, Woodward, N., additional, Nobre, A., additional, Luiz Amorim, G., additional, Califaretti, N., additional, Fox, S., additional, Robidoux, A., additional, Li, E., additional, Li, N., additional, Jiang, J., additional, Soria, T., additional, Padrik, P., additional, Lahdenpera, O., additional, Barletta, H., additional, Dohollou, N., additional, Genet, D., additional, Prulhiere, K., additional, Coeffic, D., additional, Facchini, T., additional, Vieillot, S., additional, Catala, S., additional, Teixeira, L., additional, Hesse, T., additional, Kühn, T., additional, Ober, A., additional, Repp, R., additional, Schröder, W., additional, Pectasides, D., additional, Bodoky, G., additional, Kahan, Z., additional, Jiveliouk, I., additional, Rosengarten, O., additional, Rossi, V., additional, Alabiso, O., additional, Pérez Martínez, M., additional, van de Wouw, A.J., additional, Smok-Kalwat, J., additional, Damasecno, M., additional, Augusto, I., additional, Sousa, G., additional, Saadein, A., additional, Abdelhafiez, N., additional, Abulkhair, O., additional, Antón Torres, A., additional, Corbellas Aparicio, M., additional, Llorente Domenech, R., additional, Florián Jerico, J., additional, Garcia Mata, J., additional, Gil Raga, M., additional, Galan Brotons, A., additional, Llombart Cussac, A., additional, Llorca Ferrandiz, C., additional, Martinez Del Prado, P., additional, Olier Garate, C., additional, Rodriguez Sanchez, C., additional, Sanchez Gomez, R., additional, Santisteban Eslava, M., additional, Soberino, J., additional, Vidal Losada Garcia, M., additional, Soto de Prado, D., additional, Torrego Garcia, J., additional, Vicente Rubio, E., additional, Garcia, M., additional, Murias Rosales, A., additional, Granstam Björneklett, H., additional, Narbe, U., additional, Jafri, M., additional, Rea, D., additional, Newby, J., additional, Jones, A., additional, Westwell, S., additional, Ring, A., additional, Alonso, I., additional, and Rodríguez, R., additional

Published
2021
Full Text
View/download PDF

32. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study

Author

Lasagna, A., primary, Agustoni, F., additional, Percivalle, E., additional, Borgetto, S., additional, Paulet, A., additional, Comolli, G., additional, Sarasini, A., additional, Bergami, F., additional, Sammartino, J.C., additional, Ferrari, A., additional, Zavaglio, F., additional, Arena, F., additional, Lilleri, D., additional, Secondino, S., additional, Falzoni, M., additional, Schiavo, R., additional, Klersy, C., additional, Lo Cascio, G., additional, Cavanna, L., additional, Baldanti, F., additional, Pedrazzoli, P., additional, and Cassaniti, I., additional

Published
2021
Full Text
View/download PDF

33. Human infections due to Schizophyllum commune: Case report and review of the literature

Author

Maria Carmela Esposto, Piero Marone, C. Cavanna, Francesca Tamarozzi, Fabio Pagella, L. Clemente, Fabiola Lallitto, and E. Matti

Subjects
medicine.medical_specialty, Schizophyllum, Timely diagnosis, 03 medical and health sciences, Emerging pathogen, Species level, Humans, Medicine, Sinusitis, Intensive care medicine, 0303 health sciences, biology, 030306 microbiology, business.industry, Schizophyllum commune, Sequence Analysis, DNA, Middle Aged, biology.organism_classification, medicine.disease, Rapid identification, Infectious Diseases, Italy, Mycoses, Face, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Chronic Disease, Female, Identification (biology), Tomography, X-Ray Computed, business, Immunocompetence
Abstract

Schizophyllum commune is an environmental basidiomycetous fungus, causing occasional, predominantly respiratory, infections in humans. Although S. commune is considered an emerging pathogen, some authors pointed out the possibility that the increase in the diagnosed cases may be also due to recent advances in diagnostic technologies now allowing a more prompt and precise identification at the species level. Here we describe the first Italian case of chronic non-invasive fungal rhinosinusitis due to S. commune in an immunocompetent subject and update the literature review on S. commune sinusitis published between 2012–2019. A timely diagnosis is important to avoid local and systemic complications due to infection with this fungus. In our case, prompt identification at species level was only possible with the use of MALDI-TOF mass spectrometry and confirmed by sequence analysis of ribosomal DNA ITS regions, due to the difficulty in achieving a correct and rapid identification using routine morphological analysis.

Published
2019
Full Text
View/download PDF

34. The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer

Author

M. Turazza, Nicla La Verde, Stefania Gori, Filippo Alongi, Matteo Valerio, Antonio Frassoldati, Antonio Russo, Lucio Laudadio, Ornella Garrone, Alessandro Inno, Luigi Cavanna, Alessandra Fabi, Vita Leonardi, Emiliana Tarenzi, Jennifer Foglietta, Gianluigi Lunardi, Elisabetta Cretella, Patrizia Vici, F. Marchetti, Daniele Galanti, S. Moroso, Sandro Barni, and Fabio Puglisi

Subjects
Adult, 0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Socio-culturale, Breast Neoplasms, Lapatinib, Treatment experienced, Radiosurgery, SRS, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Trastuzumab, Internal medicine, HER2 Positive Breast Cancer, Biomarkers, Tumor, medicine, Humans, Aged, Retrospective Studies, business.industry, Middle Aged, WBRT, Prognosis, medicine.disease, Combined Modality Therapy, Confidence interval, Survival Rate, Radiation therapy, Lapatinib, SRS, Surgery, Trastuzumab, WBRT, 030104 developmental biology, Receptors, Estrogen, Oncology, 030220 oncology & carcinogenesis, Surgery, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies, medicine.drug
Abstract

There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2Data of 154 patients were retrospectively collected at 14 Italian institutions through a specifically designed database.Median overall survival (OS) was 24.5 months. Patients receiving surgery/stereotactic radiosurgery experienced longer OS compared to those receiving whole-brain radiotherapy or no treatment (33.5 vs. 11.4 months; hazard ratio = 0.34; 95% confidence interval, 0.22-0.52; P .001). Interestingly, whole-brain radiotherapy did not improve OS compared to no treatment (11.4 vs. 9.8 months; hazard ratio = 0.99; 95% confidence interval, 0.62-1.62; P = .99). HER2-targeted therapy was associated with better OS compared to systemic therapy without HER2-targeted therapy or no systemic therapy (27.5 vs. 5.4 months; hazard ratio = 0.26; 95% confidence interval, 0.17-0.41; P .001). At multivariate analysis stratified by local treatments, systemic therapy, Karnofsky performance status, and neurologic symptoms significantly affected OS. Age, number of BM, steroid therapy, number of previous lines of systemic therapy, status of extracranial disease, and period of diagnosis had no significant impact on OS.Patients with BM from HER2

Published
2019
Full Text
View/download PDF

35. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial

Author

Elisa Sottotetti, Yasmina Modena, Marina Chiara Garassino, Filippo de Braud, Luca Porcu, Ugo Pastorino, Luigi Cavanna, Giuseppe Lo Russo, Federico Nichetti, Francesca Spinnato, Manlio Mencoboni, Alessandro Del Conte, Anna Paola Fraccon, Alessandro Tuzi, Daniele Pozzessere, Rosaria Gallucci, Emanuela Vattemi, Saverio Cinieri, Claudia Proto, Francesco Verderame, Diego Signorelli, Luca Giacomelli, Carla Verri, Alessandro Bertolini, Mattia Boeri, Marco Platania, Felice Pasini, Valter Torri, Paola Antonelli, Gabriella Sozzi, Antonia Martinetti, and Luciana Irtelli

Subjects
Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Platinum Compounds, Neutropenia, Vinorelbine, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Lung cancer, Aged, Neoplasm Staging, Aged, 80 and over, Chemotherapy, business.industry, Palliative Care, Induction chemotherapy, Middle Aged, medicine.disease, Survival Analysis, Regimen, 030104 developmental biology, 030220 oncology & carcinogenesis, Administration, Metronomic, Female, business, medicine.drug
Abstract

Background Oral vinorelbine administered at the maximum tolerated dose has already showed activity and a good safety profile in advanced non-small-cell lung cancer (NSCLC). The MA.NI.LA study was a phase II, multicenter, randomized, controlled trial that aimed to assess the effects of a ‘switched maintenance’ regimen with oral metronomic vinorelbine (OMV) in patients with NSCLC who had not progressed after first-line platinum-based chemotherapy. Patients and methods Patients were randomly assigned in a 1:1 ratio to either OMV (50 mg three-times weekly) as maintenance treatment or best supportive care (BSC). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective disease control rate (DCR, CR + PR + SD), safety and quality of life. Results In total, 61 and 59 patients were assigned to OMV and BSC, respectively. At a median follow-up of 23.9 (IQR 10.2–38.2) months, patients treated with OMV reported a significantly lower progression rate compared to patient in the BSC arm (89% [54/61] vs 96% [56/58]; HR 0.73; 90% CI 0.53-0.999, p = 0.049). Median PFS for patients treated with vinorelbine was 4.3 months (95% CI 2.8–5.6) vs 2.8 months (95% CI 1.9–4.5) for patients receiving BSC. This benefit was specifically evident in patients aged ≥70 years, in current smokers, and in those who reported disease stabilization as best response to induction chemotherapy. OS and response rate and quality of life were similar in the two arms. Drop-out rate for major toxicity with OMV was unexpectedly high (25%, 14/61) mainly due to grade 3–4 neutropenia (11%, 7/61). Conclusions In patients with unselected NSCLC achieving disease control after platinum-based chemotherapy switch maintenance therapy with OMV prolonged PFS compared to BSC; however, the optimal dose of OMV requires further investigation.

Published
2019
Full Text
View/download PDF

36. Ion mobility spectrometry coupled to gas chromatography: A rapid tool to assess eggs freshness

Author

Daniele Cavanna, Michele Suman, Sandro Zanardi, and Chiara Dall'Asta

Subjects
Volatile Organic Compounds, Chromatography, Chemistry, Ion-mobility spectrometry, Eggs, 010401 analytical chemistry, Extraction (chemistry), Reproducibility of Results, 04 agricultural and veterinary sciences, General Medicine, Egg product, 040401 food science, 01 natural sciences, Gas Chromatography-Mass Spectrometry, 0104 chemical sciences, Analytical Chemistry, 0404 agricultural biotechnology, Chemical marker, Ion Mobility Spectrometry, Degradation (geology), Gas chromatography, Food quality, Solid Phase Microextraction, Food Science
Abstract

Egg products freshness is a crucial problem for the production of safe and high quality food. Ion Mobility Spectrometry (IMS) coupled to Gas Chromatography (GC), provides a rapid, sensitive, cost-effective tool for the detection of freshness issues. A chemometric model was created recording the volatile fingerprints of the different egg products batches, analyzed as fresh, then left at room temperature and daily controlled: 97% was correctly predicted by the model. Beside this, a selection of chemical marker compounds, coherently related with eggs thermal degradation processes, was also identified through the exploitation of Solid-Phase Micro Extraction Gas Chromatography (SPME-GC-MS) technique and associated to the parallel IMS volatile fingerprinting. The GC-IMS system was successfully challenged with the analysis of mixtures in which the predominant component was fresh egg product and different aged eggs were progressively added as adulterants, certifying the reliability of the method also for the detection of sharper fraudulent activities.

Published
2019
Full Text
View/download PDF

40. 1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial

Author

Piccirillo, M.C., primary, Bonanno, L., additional, Garassino, M.C.C., additional, Dazzi, C., additional, Cavanna, L., additional, Esposito, G., additional, Burgio, M.A., additional, Rosetti, F., additional, Rizzato, S., additional, Arenare, L., additional, Gargiulo, P., additional, Di Liello, R., additional, De Marinis, F., additional, Crinò, L., additional, Morgillo, F., additional, Ciardiello, F., additional, Normanno, N., additional, Gallo, C., additional, Gridelli, C., additional, and Morabito, A., additional

Published
2021
Full Text
View/download PDF

41. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial

Author

Guarneri, Valentina, primary, Dieci, Maria V., additional, Griguolo, Gaia, additional, Miglietta, Federica, additional, Girardi, Fabio, additional, Bisagni, Giancarlo, additional, Generali, Daniele G., additional, Cagossi, Katia, additional, Sarti, Samanta, additional, Frassoldati, Antonio, additional, Gianni, Lorenzo, additional, Cavanna, Luigi, additional, Pinotti, Graziella, additional, Musolino, Antonino, additional, Piacentini, Federico, additional, Cinieri, Saverio, additional, Prat, Aleix, additional, and Conte, PierFranco, additional

Published
2021
Full Text
View/download PDF

42. Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia

Author

Bazarbachi, Abdul Hamid, primary, Labopin, Myriam, additional, Kröger, Nicolaus, additional, Brecht, Arne, additional, Blaise, Didier, additional, Clausen, Johannes, additional, Fanin, Renato, additional, Einsele, Herman, additional, Cavanna, Luigi, additional, Itäla-Remes, Maija, additional, Bulabois, Claude Eric, additional, Kündgen, Lukas, additional, Martin, Hans, additional, Schmid, Christof, additional, Wagner-Drouet, Eva Maria, additional, Alakel, Nael, additional, Bazarbachi, Ali, additional, Savani, Bipin, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2021
Full Text
View/download PDF

43. Evaluation of dexamethasone (DEX)-sparing regimens, administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in older patients receiving high-dose cisplatin

Author

L. Celio, D. Cortinovis, A.A. Cogoni, L. Cavanna, O. Martelli, S. Carnio, E. Collovà, F. Bertolini, F. Petrelli, A. Cassano, R. Chiari, F. Zanelli, S. Pisconti, I. Vittimberga, A. Letizia, A. Misino, A. Gernone, E. Bonizzoni, S. Pilotto, S. De Placido, and E. Bria

Subjects
Oncology, Geriatrics and Gerontology
Published
2021
Full Text
View/download PDF

44. Re: The first report on coronavirus disease 2019 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey

Author

Luigi Cavanna, Costanza Bosi, Evelina Cattadori, Chiara Citterio, and Serena Caprioli

Subjects
Cancer Research, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Cancer, medicine.disease, Vaccination, Vaccination Refusal, Oncology, Internal medicine, Vaccine refusal, medicine, business, Letter to the Editor
Published
2021
Full Text
View/download PDF

45. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

Author

A, Lasagna, F, Bergami, D, Lilleri, E, Percivalle, M, Quaccini, N, Alessio, G, Comolli, A, Sarasini, J C, Sammartino, A, Ferrari, F, Arena, S, Secondino, D, Cicognini, R, Schiavo, G, Lo Cascio, L, Cavanna, F, Baldanti, P, Pedrazzoli, and I, Cassaniti

Subjects
Vaccines, Synthetic, Cancer Research, COVID-19 Vaccines, Oncology, SARS-CoV-2, Immunoglobulin G, Neoplasms, COVID-19, Humans, Prospective Studies, mRNA Vaccines, Antibodies, Viral, BNT162 Vaccine
Abstract

Although a full course of coronavirus disease 2019 (COVID-19) vaccine is effective in cancer patients, the duration of the protection and the efficacy of a booster dose against the new variants remain unknown. We prospectively evaluated the immunogenicity of the third dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 messenger RNA vaccine in cancer patients undergoing active treatment.Patients with solid cancer, vaccinated with a booster dose during active treatment, were enrolled in this study. Patients were classified into SARS-CoV-2 naïve (without previous COVID-19 infection) and SARS-CoV-2 experienced (with previous COVID-19 infection). Neutralizing antibody (NT Ab) titer and total anti-Spike immunoglobulin G (IgG) concentration were quantified in serum. Heparinized whole blood samples were used for SARS-CoV-2 Interferon Gamma Release Assay (IGRA). The primary endpoint was to assess the increase of IgG antibody level between baseline and 3 weeks after the booster.One hundred and forty-two consecutive patients were recruited. In SARS-CoV-2-naïve subjects, the median level of IgG was 157 BAU/ml [interquartile range (IQR) 62-423 BAU/ml] at T0 and reached a median of 2080 BAU/ml (IQR 2080-2080 BAU/ml) at 3 weeks after booster administration (T1; P0.0001). A median 16-fold increase of SARS-CoV-2 NT Ab titer (IQR 4-32) was observed in naïve subjects (from median 20, IQR 10-40, to median 640, IQR 160-640; P0.0001). Median interferon-γ level at T1 was significantly higher than that measured at T0 in SARS-CoV-2-naïve subjects (P = 0.0049) but not in SARS-CoV-2-experienced patients. The median level of SARS-CoV-2 NT Abs was 32-fold lower against Omicron compared to the wild-type strain (P = 0.0004) and 12-fold lower compared to the Delta strain (P = 0.0110).The third dose is able to trigger both the humoral and the cell-mediated immune response in cancer patients on active treatment. Our preliminary data about the neutralization of the SARS-CoV-2 vaccine against variants of concern seem to confirm the lower vaccine activity.

Published
2022
Full Text
View/download PDF

46. A preliminary examination of self-concept in older adolescents and young adults with Gilles de la Tourette syndrome

Author

Francesco Cardona, Paola R. Silvestri, Flavia Chiarotti, Valentina Baglioni, Andrea E. Cavanna, Valeria Neri, Silvestri, P, Chiarotti, F, Baglioni, V, Neri, V, Cardona, F, and Cavanna, A

Subjects
Male, Gilles de la Tourette syndrome, medicine.medical_specialty, Adolescent, Tics, Psychological intervention, Self-concept, Comorbidity, Affect (psychology), Tourette syndrome, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Surveys and Questionnaires, medicine, Humans, adolescents, Young adult, Psychiatry, Competence (human resources), Depression, Mental Disorders, Tourette Syndrome, anxiety, General Medicine, medicine.disease, Self Concept, 030227 psychiatry, Pediatrics, Perinatology and Child Health, Quality of Life, Psychiatric co-morbiditie, Anxiety, Female, Neurology (clinical), medicine.symptom, Psychology, 030217 neurology & neurosurgery
Abstract

Introduction Gilles de la Tourette syndrome (GTS) is a childhood-onset neuropsychiatric disorder characterised by multiple tics and often associated with behavioural problems. Although there is evidence of significantly reduced self-esteem in children and adolescents with GTS, little is known about perceived self-concept and its clinical determinants at the transition age between adolescence and adulthood. We therefore set out to investigate self-concept in a clinical sample of young patients with GTS at this crucial age for personal development. Methods In addition to standard demographic and clinical data, we collected self-ratings using a standardised battery of psychometric instruments, as well as the Multidimensional Self Concept Scale, a comprehensive questionnaire developed to assess self-concept in subjects aged 9– to 19 years, tapping into the social, competence, affect, academic, family, and physical domains. Results We found that patients diagnosed with at least one co-morbid psychiatric disorder (“GTS-plus” phenotype) reported significantly lower self-concept than patients with “pure GTS”, whereas tic-related variables had no impact on self-concept. Anxiety symptoms were the main determinants of self-concept, especially trait anxiety with regard to social and affective domains. Affective symptoms could also have a negative impact on the physical, affective, competence, and social domains of self-concept. Conclusion Routine screening for anxiety and affective symptoms should be recommended in all patients with GTS seen at transition clinics from paediatric to adult care, in order to implement effective treatment interventions whenever possible.

Published
2017
Full Text
View/download PDF

47. 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

Author

Conte, P.F., primary, Frassoldati, A., additional, Bisagni, G., additional, Brandes, A.A., additional, Donadio, M., additional, Garrone, O., additional, Piacentini, F., additional, Cavanna, L., additional, Giotta, F., additional, Aieta, M., additional, Gebbia, V., additional, Musolino, A., additional, Ferro, A., additional, Danese, S., additional, Zamagni, C., additional, Nanni, O., additional, Dieci, M.V., additional, Vicini, R., additional, Balduzzi, S., additional, and Guarneri, V., additional

Published
2021
Full Text
View/download PDF

48. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial

Author

Cascinu, Stefano, primary, Berardi, Rossana, additional, Bianco, Roberto, additional, Bilancia, Domenico, additional, Zaniboni, Alberto, additional, Ferrari, Daris, additional, Mosconi, Stefania, additional, Spallanzani, Andrea, additional, Cavanna, Luigi, additional, Leo, Silvana, additional, Negri, Francesca, additional, Beretta, Giordano D., additional, Sobrero, Alberto, additional, Banzi, Maria, additional, Morabito, Alberto, additional, Bittoni, Alessandro, additional, Marciano, Roberta, additional, Ferrara, Domenica, additional, Noventa, Silvia, additional, Piccirillo, Maria C., additional, Labianca, Roberto, additional, Mosconi, Cristina, additional, Casadei Gardini, Andrea, additional, Gallo, Ciro, additional, and Perrone, Francesco, additional

Published
2021
Full Text
View/download PDF

49. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

Author

Rosati, Gerardo, primary, Lonardi, Sara, additional, Galli, Fabio, additional, Di Bartolomeo, Maria, additional, Ronzoni, Monica, additional, Zampino, Maria G., additional, Banzi, Maria, additional, Zaniboni, Alberto, additional, Pasini, Felice, additional, Bozzarelli, Silvia, additional, Garattini, Silvio K., additional, Ferrari, Daris, additional, Montesarchio, Vincenzo, additional, Mambrini, Andrea, additional, Ciuffreda, Libero, additional, Galli, Francesca, additional, Pusceddu, Valeria, additional, Carlomagno, Chiara, additional, Bidoli, Paolo, additional, Amoroso, Domenico, additional, Bochicchio, Anna M., additional, Frassineti, Luca, additional, Corsi, Domenico, additional, Bilancia, Domenico, additional, Pastorino, Alessandro, additional, De Stefano, Alfonso, additional, Labianca, Roberto, additional, Bilancia, D., additional, Rosati, G., additional, Montesarchio, V., additional, Iaffaioli, R.V., additional, Nasti, G., additional, Daniele, B., additional, Zagonel, V., additional, Lonardi, S., additional, Pella, N., additional, Aprile, G., additional, Pasini, F., additional, Marchetti, Roma P., additional, Romiti, A., additional, Ciuffreda, L., additional, Ferrari, D., additional, Foa, P., additional, Zaniboni, A., additional, Labianca, R., additional, Mosconi, S., additional, Sobrero, A., additional, Bidoli, P., additional, Cazzaniga, M., additional, Beretta, G.D., additional, Corsi, D.C., additional, Cortesi, E., additional, Barni, S., additional, Petrelli, F., additional, Allione, P., additional, D'Arco, A.M., additional, Valmadre, G., additional, Piazza, E., additional, Veltri, E., additional, Ramus, G. Vietti, additional, Giustini, L., additional, Tumulo, S., additional, Cascinu, S., additional, Granetto, C., additional, Testore, F., additional, Giordano, M., additional, Moroni, M., additional, Di Seri, M., additional, Nuzzo, A., additional, Angelelli, L., additional, Gori, S., additional, Farina, G., additional, Aglietta, M., additional, Franchi, R., additional, Comandé, M., additional, Giordani, P., additional, Tonini, G., additional, Bucci, E., additional, Ballestrero, A., additional, Benasso, M., additional, Graiff, C., additional, Bravi, S., additional, Caffo, O., additional, Silva, R.R., additional, Frontini, L., additional, Rota, S., additional, Cozzi, L., additional, Cantore, M., additional, Maiello, E., additional, Cinieri, S., additional, Silvestris, N., additional, Romito, S., additional, Gebbia, V., additional, Banzi, M., additional, Santoro, A., additional, Artioli, F., additional, Mattioli, R., additional, Contu, A., additional, Di Costanzo, F., additional, Leonardi, F., additional, Cavanna, L., additional, Passalacqua, R., additional, Amoroso, D., additional, Sozzi, P., additional, D'Amico, M., additional, Amadori, D., additional, Frassineti, L., additional, Turci, D., additional, Ravaioli, A., additional, Pasquini, E., additional, Gambi, A., additional, Faedi, M., additional, Cruciani, G., additional, Bajetta, E., additional, Di Bartolomeo, M., additional, Gianni, L., additional, Ronzoni, M., additional, Ionta, M.T., additional, Massidda, B., additional, Scartozzi, M., additional, Zampino, M.G., additional, Bochicchio, A.M., additional, Ciarlo, A., additional, Di Leo, A., additional, Frustaci, S., additional, Rangoni, G., additional, Arizzoia, A., additional, Pavesi, L., additional, Verusio, C., additional, Pinotti, G., additional, Iop, A., additional, De Placido, S., additional, Carlomagno, C., additional, Adamo, V., additional, Ficorella, C., additional, Natale, D., additional, Greco, E., additional, Rulli, E., additional, Galli, F., additional, Poli, D., additional, Porcu, L., additional, and Torri, V., additional

Published
2021
Full Text
View/download PDF

50. Characterization of the LUNA neutron detector array for the measurement of the 13C(α, n)16O reaction

Author

Csedreki, L., primary, Ciani, G.F., additional, Balibrea-Correa, J., additional, Best, A., additional, Aliotta, M., additional, Barile, F., additional, Bemmerer, D., additional, Boeltzig, A., additional, Broggini, C., additional, Bruno, C.G., additional, Caciolli, A., additional, Cavanna, F., additional, Chillery, T., additional, Colombetti, P., additional, Corvisiero, P., additional, Davinson, T., additional, Depalo, R., additional, Di Leva, A., additional, Elekes, Z., additional, Ferraro, F., additional, Fiore, E.M., additional, Formicola, A., additional, Fülöp, Zs., additional, Gervino, G., additional, Guglielmetti, A., additional, Gustavino, C., additional, Gyürky, Gy., additional, Imbriani, G., additional, Janas, Z., additional, Junker, M., additional, Kochanek, I., additional, Lugaro, M., additional, Marigo, P., additional, Masha, E., additional, Mazzocchi, C., additional, Menegazzo, R., additional, Mossa, V., additional, Pantaleo, F.R., additional, Paticchio, V., additional, Perrino, R., additional, Piatti, D., additional, Prati, P., additional, Schiavulli, L., additional, Stöckel, K., additional, Straniero, O., additional, Szücs, T., additional, Takács, M.P., additional, Terrasi, F., additional, and Zavatarelli, S., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results